An exclusive collection of ovarian cancer PDX models, developed from patients with a CCNE1 over expression, perfect for the investigation of mechanisms of resistance and assessing novel therapeutics
Now Enrolling until February 27th, 2026
Translationally Accurate CCNE1 Amplified PDX Models
CCNE1 amplification drives uncontrolled G1–S progression, replication stress, and genomic instability, creating tumors that are fast growing and highly resistant. Champions’ CCNE1 Amplified PDX Screen models this biology with precision.
This platform features low passage PDX models derived from CCNE1 amplified patient tumors, preserving the key molecular hallmarks of this genotype, including dysregulated cell cycle control, altered DNA repair dependencies, and clinically consistent resistance patterns. Built for teams developing DDR inhibitors, CDK2 or WEE1 strategies, synthetic lethality approaches, or rational combinations, this screen enables clear readouts of mechanism, vulnerability, and translational potential.
What Makes This Screen Unique
-
Clinically Relevant ModelsLow passage CCNE1 amplified PDX models preserving aggressive biology, genomic instability, and real resistance patterns.
-
True CCNE1 FidelityModels retain dysregulated cell cycle signaling and replication stress phenotypes essential for accurate mechanism testing.
-
Translational Multi-omicsMatched clinical histories, WES, RNAseq, proteomics, and biomarker data available through Lumin for deeper insights.
-
Replicative Stress BiologyIdeal for evaluating DDR, CDK2, WEE1, and synthetic lethality strategies under clinically consistent stress conditions.
-
Combination Strategy ReadySupports rational testing of targeted combinations designed to exploit CCNE1 driven DNA repair dependencies.
-
Mechanism of Action ClarityEnables clean readouts of pathway modulation, vulnerability, and resistance mechanisms across diverse solid tumors.
Collaborative Benchmarking Arm (Shared SoC)
Clients participating in this CCNE1 Amplified PDX Screen can access a cost-shared Standard of Care reference arm to benchmark therapeutic responses and reduce study investment.
SoC Agent and Dosing:
Adavosertib: 120mg/kg; po; qd (up to 28 days)
Ceralasertib: 25mg/kg; po; 2qd x7 rest 14 days (2 cycles) (up to 28 days)
CCNE1 PDX Model Screen
Our screen includes 17 ovarian models from patients with a CCNE1 over expression.
|
Model
|
Tumor type
|
Gene
|
Log²TPM
|
|---|---|---|---|
|
CTG-4198
|
Ovarian
|
CCNE1
|
8.14
|
|
CTG-0958
|
Ovarian
|
CCNE1
|
7.69
|
|
CTG-2561
|
Ovarian
|
CCNE1
|
7.55
|
|
CTG-3423
|
Ovarian
|
CCNE1
|
7.06
|
|
CTG-4125
|
Ovarian
|
CCNE1
|
6.94
|
|
CTG-4284
|
Ovarian
|
CCNE1
|
6.82
|
|
CTG-3331
|
Ovarian
|
CCNE1
|
6.67
|
|
CTG-1305
|
Ovarian
|
CCNE1
|
6.51
|
|
CTG-3327
|
Ovarian
|
CCNE1
|
6.28
|
|
CTG-1692
|
Ovarian
|
CCNE1
|
6.19
|
|
CTG-3718
|
Ovarian
|
CCNE1
|
6.05
|
|
CTG-0992
|
Ovarian
|
CCNE1
|
5.96
|
|
CTG-0711
|
Ovarian
|
CCNE1
|
5.62
|
|
CTG-1180
|
Ovarian
|
CCNE1
|
3.07
|
|
CTG-1834
|
Ovarian
|
CCNE1
|
2.72
|
|
CTG-0486
|
Ovarian
|
CCNE1
|
2.64
|
|
CTG-1677
|
Ovarian
|
CCNE1
|
2.34
|